Case series of intravenous thrombolysis for acute ischemic stroke in confirmed COVID-19 patients: single-centre experience

Case series of intravenous thrombolysis for acute ischemic stroke in confirmed COVID-19 patients: single-centre experience

Abstract Background Coronavirus disease 2019 (COVID-19) not only caused a large surge of respiratory infections, it also had a potential association with and increases the risk of stroke. The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke...

Full description

Bibliographic Details
Main Authors: Ahmad Sulaiman Alwahdy, Ika Yulieta Margaretha, Kenyo Sembodro Pramesti, Nailaufar Hamro, Viska Yuzella, Fitriani Nasution, Arfan Mappalilu
Format: Article
Language:English
Published: SpringerOpen 2022-01-01
Series:The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Subjects:
Ischemic stroke
Intravenous thrombolysis
Rt-PA
COVID-19
Case series
Online Access:https://doi.org/10.1186/s41983-021-00434-w
Description
Summary:Abstract Background Coronavirus disease 2019 (COVID-19) not only caused a large surge of respiratory infections, it also had a potential association with and increases the risk of stroke. The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke (AIS); however, data regarding outcomes of intravenous tissue plasminogen activator (IV TPA) administration in stroke patients with COVID-19 remains limited. Case presentation Three AIS patients with confirmed COVID-19 treated using IV tPA. One case had excellent outcome, while the other cases showed unfavorable results. The risk–benefit ratio of IV TPA in COVID-19 remains unclear. Conclusion In this article, we discuss the possible explanation behind these different outcomes. Although IV tPA could not cure COVID-19, we suggest that its administration should not be delayed in AIS patients with COVID-19.
ISSN:1687-8329

Similar Items